Vical Incorporated Stock Nasdaq
Equities
US9256021042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 15 | Fresh Tracks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index | CI |
Financials (USD)
Sales 2022 | 6.94M | Sales 2023 | 8.01M | Capitalization | 5.25M |
---|---|---|---|---|---|
Net income 2022 | -21M | Net income 2023 | -5M | EV / Sales 2022 | -0.59 x |
Net cash position 2022 | 8.63M | Net cash position 2023 | 10.87M | EV / Sales 2023 | -0.7 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.4% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 20-11-30 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 15-12-31 |
Aaron Fox-Collis
AUD | Comptroller/Controller/Auditor | - | 20-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 72 | 20-11-30 |
1st Jan change | Capi. | |
---|---|---|
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |